Thursday, 9 October 2014

Community Immunity: How Vaccines Protect Us All

Community Immunity

How Vaccines Protect Us All


Parents know that kids are vulnerable to a host of infectious diseases. Research supported by NIH and others proves that the benefits of vaccines in preventing illness and death greatly outweigh the risks.
The list of childhood diseases can be overwhelming: measles, mumps, rubella, diphtheria, pertussis, polio, meningitis, influenza and rotavirus. In the era before vaccines, many children in the U.S. died or became disabled from these diseases. Many still do in countries and regions with lower vaccination rates.
With all the international travel in the world these days, it’s important to keep vaccines, or immunizations, up to date. Here’s just one example of what might happen if you don’t. By 2000, immunization had practically wiped out measles in the U.S. But a measles outbreak in 2005 was traced to one unvaccinated U.S. resident infected during a visit to Europe. The returning traveler infected American children who hadn’t been vaccinated because of safety concerns—despite study after study showing that childhood vaccines are safe and effective.
A major epidemic didn’t emerge that time. That’s because enough people in the surrounding communities had already been vaccinated against measles.
“The important concept,” says Dr. Marc Lipsitch of the Harvard School of Public Health, “is that vaccinating people protects not only them, but others in the community. If I’m protected, I can protect others.”
This type of protection is known as “community immunity” or “herd immunity.”  When enough of the community is immunized against a contagious disease, most other members are protected from infection because there’s little opportunity for the disease to spread.
Newborns, pregnant women or people whose immune systems are weakened may not be eligible for certain vaccines. Yet even they will get some protection because the spread of contagious disease is contained.
“Epidemiologists think of infections as chain reactions, whose speed depends on contagiousness,” says Lipsitch. “The more contagious the disease, the more vaccination is required. The data tells us that herd immunity works.”
Using mathematical formulas and computer programs, NIH-funded scientists like Lipsitch have developed models to determine what proportion of the population has to be vaccinated to eliminate the spread of disease. As one example, a worldwide vaccination campaign completely eliminated, or eradicated, smallpox in the 1970s. So many people were immunized that the virus couldn’t sustain itself.
More recently, infant vaccination against Haemophilus influenzae type b (Hib, which can cause meningitis) lowered the risk of disease in the whole population. Before the vaccine, Hib struck about 1 in 200 children younger than age 5. It killed many and often left survivors with permanent brain damage. After the Hib vaccine was introduced in the mid-1980s, the incidence of Hib dropped by 99%.
“Infectious disease eradication is possible,” says Lipsitch. Even when a disease—such as measles or Hib— hasn’t been completely wiped out, immunizations can reduce disease transmission, so that epidemics become less frequent.

Wednesday, 8 October 2014

Ingredients of Vaccines

Ingredients of Vaccines


Chemicals commonly used in the production of vaccines include a suspending fluid (sterile water, saline, or fluids containing protein); preservatives and stabilizers (for example, albumin, phenols, and glycine); and adjuvants or enhancers that help improve the vaccine's effectiveness. Vaccines also may contain very small amounts of the culture material used to grow the virus or bacteria used in the vaccine, such as chicken egg protein.


Important Facts
  • Millions of doses of vaccines are administered to children in this country each year. Ensuring that those vaccines are potent, sterile, and safe requires the addition of minute amounts of chemical additives.
  • Chemicals are added to vaccines to inactivate a virus or bacteria and stabilize the vaccine, helping to preserve the vaccine and prevent it from losing its potency over time.
  • The amount of chemical additives found in vaccines is very small.
  • All routinely recommended pediatric vaccines manufactured for the U.S. market are available in formulations that contain no thimerosal or only trace amounts.

Common substances found in vaccines include:
  • Aluminum gels or salts of aluminum which are added as adjuvants to help the vaccine stimulate a better response. Adjuvants help promote an earlier, more potent response, and more persistent immune response to the vaccine. 

  • Antibiotics which are added to some vaccines to prevent the growth of germs (bacteria) during production and storage of the vaccine. No vaccine produced in the United States contains penicillin.
  • Egg protein is found in influenza and yellow fever vaccines, which are prepared using chicken eggs. Ordinarily, persons who are able to eat eggs or egg products safely can receive these vaccines.
  • Formaldehyde is used to inactivate bacterial products for toxoid vaccines, (these are vaccines that use an inactive bacterial toxin to produce immunity.) It is also used to kill unwanted viruses and bacteria that might contaminate the vaccine during production. Most formaldehyde is removed from the vaccine before it is packaged.
  • Monosodium glutamate (MSG) and 2-phenoxy-ethanol which are used as stabilizers in a few vaccines to help the vaccine remain unchanged when the vaccine is exposed to heat, light, acidity, or humidity.
  • Thimerosal is a mercury-containing preservative that is added to vials of vaccine that contain more than one dose to prevent contamination and growth of potentially harmful bacteria.
For children with a prior history of allergic reactions to any of these substances in vaccines, parents should consult their child’s healthcare provider before vaccination.

Tuesday, 7 October 2014

Routine Mumps Immunization

Routine Mumps Immunization

What arguments can be brought against immunization for childhood diseases and specifically mumps? It is everyday experience in general practice that parents do not see childhood diseases as harmful to humans, in spite of possible complications, but as a biographical event with potential significance for their child's development. This view, based on feelings and experience, still needs scientific proof, but it would be disastrous if absence of proof were made the reason to ignore this definite opposition to the MMR immunization campaign when designing further campaigns.

For centuries, the microorganisms involved in childhood diseases such as mumps, measles and rubella showed a balanced relationship to the human population. Mass immunizations represent massive artificial intervention in those balances, with potentially unforeseeable consequences.

Epidemics are, above all, feared in populations where immunity to a particular pathogen has been lost because the disease has not occurred for some time. H. Stickl expressed concern even with regard to smallpox: "After the last case of smallpox, with the disease not recorded anywhere on earth for twice five years, which is the usual epidemic wavelength for smallpox, there was no longer any convincing reason for smallpox vaccination. Initially this was a great advantage. On careful reflection, it is evident, however, that in less than one generation an unvaccinated European population will reach the state which pertained prior to the great migrations of the 4th to 6th Century, i.e. before smallpox became endemic. People may then be expected to be completely receptive to smallpox virus infection.

Both physicians and parents would be against enforcing the higher level of compliance needed to continue the campaign. This would mean imposing government views on the Swiss health system when there is no need from the public health point of view. Constitutional lawyers doubt, however, that the limitation of basic rights in such an enforced measure would meet the requirements of suitability and reasonability.

This susceptibility to failure means that enforced measures become increasingly necessary to limit relapse epidemics. They include ensuring and maintaining immunization of the whole population, monitoring the immunity of the population, and monitoring virus circulation on borders and in quarantine situations, as well as barrier immunization procedures to limit outbreaks.

Monday, 6 October 2014

Performance and determinants of routine immunization coverage within the context of intensive polio eradication activities in Uttar Pradesh, India: Social Mobilization Network

Performance and determinants of routine immunization coverage within the context of intensive polio eradication activities in Uttar Pradesh, India: Social Mobilization Network



Background

Studies that have looked at the effect of polio eradication efforts in India on routine immunization programs have provided mixed findings. One polio eradication project, funded by US Agency for International Development (USAID) and carried out by the CORE Group Polio Project (CGPP) in the state of Uttar Pradesh of India, has included the strengthening of routine immunization systems as a core part of its polio eradication strategy. This paper explores the performance of routine immunization services in the CGPP intervention areas concurrent with intensive polio eradication activities. The paper also explores determinants of routine immunization performance such as caretaker characteristics and CGPP activities to strengthen routine immunization services.

Methods

Secondary data analysis of the latest project household immunization survey in 2011 was conducted and compare these findings to reports of past surveys in the CGPP program area and at the Uttar Pradesh state level (as measured by children’s receipt of DPT vaccinations). This is done to judge if there is any evidence that routine immunization services are being disrupted. We also model characteristics of survey respondents and respondents’ exposure to CGPP, communication activities against their children’s receipt of key vaccinations in order to identify determinants of routine immunization coverage.

Results

Routine immunization coverage has increased between the first survey (2005 for state level estimates, 2008 for the CGPP program) and the latest (2011 for both state level and CGPP areas), as measured by children’s receipt of DPT vaccination. This increase occurred concurrent with polio eradication efforts intensive enough to result in interruption of transmission. In addition, a mothers’ exposure to specific communication materials, her religion and education were associated with whether or not her children receive one or more doses of DPT.

Conclusions

A limitation of the analysis is the absence of a controlled comparison. It is possible routine immunization coverage would have increased even more in the absence of polio eradication efforts. At the same time, however, there is no evidence that routine immunization services were disrupted by polio eradication efforts. Targeted health communications are helpful in improving routine immunization performance. Strategies to address other determinants of routine immunization, such as religion and education, are also needed to maximize coverage.

Sunday, 5 October 2014

IMMUNIZATION: ACHIEVEMENTS AND CHALLENGES

ACHIEVEMENTS 
Over the past decade, immunization programmes have added new and underused 
vaccines to the original six – diphtheria, tetanus, pertussis, measles, polio, and 
tuberculosis – given to young children. They include vaccines against hepatitis B, 
Haemophilus influenzae type b (Hib) disease, mumps, pneumococcal disease, 
rotavirus, rubella, and – in countries where needed – yellow fever and Japanese 
encephalitis
Immunization averts an estimated 2.5 million child deaths a year, but despite the 
successes, millions of children in developing countries – almost 20% of all children 
born every year – do not get the complete immunizations scheduled for their first 
year of life. 

BARRIERS TO INCREASE IMMUNIZATION
Reaching these children will require overcoming a number of critical barriers that have 
slowed progress. A major barrier is the underlying weakness of the health system 
in many developing countries. Another is the difficulty in delivering vaccines through 
an infrastructure and logistical support system that is often overloaded. Yet another 
is a lack of understanding about the importance of vaccines – especially among 
the poorest populations – and a failure to actively demand access to immunization 
services. The threat posed by false or unsubstantiated rumours about vaccine safety 
is also a barrier to progress, as is the projected shortfall in funding needed to reach 
the global immunization-related goals.
Efforts under way to overcome the barriers to expanded immunization include the 
use of immunization campaigns and “outreach” operations that seek out population 
groups not adequately covered by routine immunization programmes. In addition, 
special initiatives, such as the Optimize project, have been launched to help countries 
manage the growing complexity of immunization logistics (delivery and storage of 
vaccines, for example) underpinning immunization activities.

STRATEGIES FOLLOWED TO PROMOTE IMMUNIZATION
 The Reaching Every District (RED) strategy, launched in 2002, is designed to 
strengthen immunization delivery at the district level, by encouraging district-level 
immunization officials to adopt the principles of “good immunization practice”, such 
IMAGE PROMOTING IMMUNIZATION
as the identification and resolution of local problems, the organization of regular 
outreach vaccine delivery services, and the involvement of communities in ensuring 
adequate functioning of immunization services.
 Another strategy aims to integrate immunization activities with other services 
provided by the health system. Any contact that a health worker has with a child or mother at a health facility is also an opportunity to check immunization status and, 
if need be, to administer vaccines. Conversely, a mobile team offering immunization 
to a community can also distribute medicines, antimalarial bednets, and other health 
commodities or interventions.
Community participation is a key factor in raising vaccine coverage. Creating 
awareness of, and public demand for, the benefits of immunization is an essential 
component of an active immunization programme. However, it is also important to 
ensure that demand can be reliably met. 

Friday, 3 October 2014

NATIONAL IMMUNIZATION
SCHEDULE 

Every country follows an immunization schedule here is a chart of  India's immunization schedule for pregnant women, infants and children...


Thursday, 2 October 2014

TYPES OF VACCINATION [VARICELLA]

VARICELLA 
[CHICKEN POX VACCINE]

About the disease...
Chickenpox (varicella) is a disease caused by a virus. Most people with chickenpox get very itchy blisters and sores all over their body.Chickenpox is spread person-to-person through the air. It is very contagious. Chickenpox can be a serious disease, especially in babies and adults. The disease can cause serious skin infections, pneumonia, brain damage, and even death. Chickenpox is especially dangerous for people whose immune systems are weak because of illness or medications.It is extremely contagious and can be spread by an infected person before they even know they're sick.Vaccination is the most effective step you can take to be protected from this serious disease.

More about the Vaccine...
The chickenpox vaccine is a shot that can protect nearly everyone who gets it from catching chickenpox. It's also called the varicella vaccine, because chickenpox is caused by the varicella-zoster virus. The vaccine is made from a live but weakened, or attenuated, virus.
Viruses that have been attenuated are less virulent than viruses that are not. Although the virus in the chickenpox vaccine is generally incapable of causing a disease, it still stimulates a response from the body's immune system. That response is what gives someone who's had a shot for chickenpox immunity or protection from the illness.
Importance of the Vaccine...
Most cases of chickenpox are relatively mild and run their course in five to 10 days. But it can be very serious, even life-threatening, in a small percentage of people.The risk of serious, life-threatening complications is greatest among infants, adults, and people with weakened immune systems. But anyone can develop serious complications and there is no way to predict who will.
There's another reason for getting a shot for chickenpox. The illness is highly contagious and can be spread by direct contact or through the air by sneezing or coughing. Also, someone can get it by coming in contact with fluid from chickenpox blisters. For that reason, children with chickenpox need to be kept out of school or day care for about a week or more until all blisters have dried and crusted over. The illness causes an itchy rash that usually forms between 200 and 500 blisters over the entire body, headaches, coughing, and fussiness. So even if the illness is mild, it still means five to 10 days of being uncomfortable.
Vaccine Schedule...
All children should get 2 doses of chickenpox vaccine starting at age 1. Some teens and adults may also need this vaccine if they didn't get 2 doses of the vaccine or chickenpox disease when they were younger.

Wednesday, 1 October 2014

TYPES OF VACCINATION[Meningococcal]

MENINGOCOCCAL VACCINE

About the disease...
Meningococcal disease  is an infection caused by a strain of bacteria called Neisseria meningitidis. This nasty bug is one of the leading causes of bacterial meningitis  in children aged 2 to 18.
Meningococcal disease can include meningitis -- a serious, potentially life-threatening inflammation of the membranes covering the brain and spinal cord -- and a life-threatening blood infection. Meningococcal disease can cause limb loss through amputation, hearing loss, problems with the nervous system, mental retardation, seizures, and strokes.
Fortunately, meningococcal disease is preventable, and the key to prevention is the meningococcal vaccine.

Symptoms of the disease...



More about Meningococcal Vaccine..
The first vaccine -- meningococcal polysaccharide vaccine or MPSV4 -- was approved in 1978. It's made with the antigens contained in the outer polysaccharide or sugar capsule that surrounds the bacterium.
The newer vaccine, approved in 2005, is the meningococcal conjugate vaccine or MCV4. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body's immune cells. This makes it easier for the body's immune system to see and recognize the antigens.
One type of MCV4, Menveo, is licensed for use in people aged 2 to 55. Another version, Menactra, is approved for those 9 months to 55 years old. MPSV4 is the only vaccine licensed for use in people over 55 as well as people 2 to 55. Both vaccines protect against four types of meningococcal disease.
Effectiveness of the Vaccine..
Both MCV4 and MPSV4 are about 90% effective in preventing meningococcal disease. There are actually several types of N meningitidis -- the bacterium that causes meningococcal disease.Both vaccines protect against four of those types.
MCV4 has not been available long enough to compare the long-term effectiveness of the two vaccines. But most experts think that MCV4 provides better, longer-lasting protection. 

Saturday, 27 September 2014

TYPES OF VACCINATION [Pneumococcal]

PNEUMOCOCCAL VACCINE

About Pneumococcal disease..
Pneumococcal disease is an infection caused by the bacteria Streptococcus pneumoniae or pneumococcus. People can be infected with the bacteria, or they can carry it in their throat, and not be ill. Those carriers can still spread it, primarily in droplets from their nose or mouth when they breathe, cough, or sneeze.
Depending on what organ or part of the body is infected, pneumococcal disease will cause any of several serious illnesses, including:
  • Bacterial meningitis, an infection of the covering of the brain and spinal cord that can lead to confusion, coma, and death as well as other physical effects, such as blindness or paralysis
  • Pneumonia, an infection of the lungs and a common bacterial complication of influenza otitis media, a middle ear infection that can cause pain, swelling, sleeplessness, fever, and irritability
  • Bacteremia, a dangerous infection of the blood stream
  • Sinus infections
Pneumococcal Vaccine..

Pneumococcal conjugate vaccine (PCV13) is recommended for all children younger than 5 years old, all adults 65 years or older, and people 6 years or older with certain risk factors.Pneumococcal polysaccharide vaccine (PPSV23) is recommended for all adults 65 years or older. People 2 years through 64 years of age who are athigh risk of pneumococcal disease should also receive PPSV23.
This vaccine protects against pneumococcal infections, which mostly strike children under age 5 and can lead to some of the worst childhood diseases. Pneumococcal infections are one of the most common causes of death in the United States from a disease that's preventable with a vaccine.
The pneumococcal conjugate vaccine, PCV13 or Prevnar 13®, is currently recommended for all children younger than 5 years of age, all adults 65 yea

rs or older, and persons 6 through 64 years of age with certain medical conditions.
Pneumovax® is a 23-valent pneumococcal polysaccharide vaccine (PPSV23) that is currently recommended for use in all adults 65 years of age or older and for persons who are 2 years and older and at high risk for pneumococcal disease (e.g., those with sickle cell disease, HIV infection, or other immunocompromising conditions). PPSV23 is also recommended for use in adults 19 through 64 years of age who smoke cigarettes or who have asthma.

Friday, 26 September 2014

TYPES OF VACCINATION [ROTAVIRUS]

ROTAVIRUS VACCINATION

Rotavirus Infection..

Rotavirus is the leading cause of severe acute gastroenteritis (vomiting and severe diarrhea) among children worldwide.Rotavirus disease is highly contagious. The germ is present in the stool of an infected person and can remain viable for a long time on contaminated surfaces, including people's hands. Children catch it by touching something that's contaminated and then putting their hands in their mouth. The spread of rotavirus infection is a particular problem in hospitals and in day care settings, where it can be easily spread from child to child. It's also easily spread by day care workers, especially when they change diapers without washing their hands afterward.

Symptoms of rotavirus infection..

More about Rotavirus vaccine..
Two brands of rotavirus vaccine are available. Your baby will get either 2 or 3 doses, depending on which vaccine is used.
Doses of rotavirus vaccine are recommended at these ages:
  • First Dose: 2 months of age
  • Second Dose: 4 months of age
  • Third Dose: 6 months of age (if needed)
Rotavirus vaccine is a liquid that is swallowed, not a shot.
Rotavirus vaccine may safely be given at the same time as other vaccines.
Rotavirus vaccine is very good at preventing diarrhea and vomiting caused by rotavirus. Almost all babies who get rotavirus vaccine will be protected from severe rotavirus diarrhea. And most of these babies will not get rotavirus diarrhea at all. The vaccine will not prevent diarrhea or vomiting caused by other germs.
Studies of the rotavirus vaccine have shown that it can prevent about 74% of rotavirus infections. More importantly, it can prevent approximately 98% of severe infections and 96% of hospitalizations from rotavirus. In one Massachusetts hospital, in two years, the number of people with rotavirus dropped from 65 to three. 

Thursday, 25 September 2014

TYPES OF VACCINATION [MEASLES]

MEASLES VACCINATION

Measles is the most deadly of all childhood rash/fever illnesses. The disease spreads very easily, so it is important to protect against infection. Getting vaccinated is the best way to prevent measles.
About the Vaccine..
Measles vaccine is given for protection against measles, the typical extemporaneous fever of childhood. It is a live viral vaccine. It is available in lyophilized form as powder in a bulb. Diluent is distilled water & is available as a separate ampoule. It is available as mono-dose or as multi-dose containing 2 or 5 doses. The final volume of reconstituted vaccine is 0.5 ml per dose. 
Measles vaccine is usually administered as MMR, a combination vaccine that provides protection against three viral diseases: measles,mumps and rubella. MMRV vaccine is licensed for children 12 months to 12 years of age and may be used in place of MMR vaccine if varicella vaccination is needed in addition to measles, mumps, and rubella vaccination. 

Dosage direction..

For children 2 doses are recommended
  • The first dose at 12–15 months of age
  •  The second dose before entering school, at 4–6 years of age
For adults 2 doses are recommended who are at higher risk, such as:
  • College students, trade school students, or other students beyond high school
  • Those who work in a hospital or other medical facility
  • International travelers or those who are passengers on a cruise ship
  • Women of childbearing age  
However, pregnant women should wait to get MMR vaccine until after they have given birth. Women should not become pregnant for 28 days following the receipt of the MMR vaccine or any of its components. (The combination MMRV vaccine is not licensed for those over 12 years old.)

Wednesday, 24 September 2014

TYPES OF VACCINATION [DTaP]

DTap Vaccination

{Diphtheria, Tetanus, Pertussis}

Understanding the Disease

Tetanus (Lockjaw) is caused by toxin-producing spores of a bacterium, Clostridium tetani that inhabit the soil and the bowels of animals and humans. Unlike other vaccine-preventable diseases, it is not spread from person to person. Tetanus infection is most often the result of wound contamination in an unimmunized person or someone who has not had vaccine boosters in many years. Tetanus may occur following delivery in the newborn babies of unimmunized women. It may also occur following puncture wounds, animal bites, burns, abrasions and surgery.
The tetanus toxin causes severe muscle contractions, or spasms. Fever, sweating, elevated blood pressure, and rapid heart rate may also occur. Spasms of the vocal cords or the muscles of respiration can interfere with breathing, and pneumonia is common. Contraction of muscles can be so severe that the spine or other bones are fractured.
Between 40-60 cases of tetanus are reported in the United States each year, and 30% of those infected die. Death is more likely in newborn infants of unimmunized mothers and patients over 50 years of age.

Why get Vaccinated?

Diphtheria, tetanus, and pertussis are serious diseases caused by bacteria. Diphtheria and pertussis are spread from person to person. Tetanus enters the body through cuts or wounds.
DIPHTHERIA causes a thick covering in the back of the throat.
  • It can lead to breathing problems, paralysis, heart failure, and even death.
TETANUS (Lockjaw) causes painful tightening of the muscles, usually all over the body.
  • It can lead to "locking" of the jaw so the victim cannot open his mouth or swallow. Tetanus leads to death in up to 2 out of 10 cases.
PERTUSSIS (Whooping Cough) causes coughing spells so bad that it is hard for infants to eat, drink, or breathe. These spells can last for weeks.
  • It can lead to pneumonia, seizures (jerking and staring spells), brain damage, and death.
Diphtheria, tetanus, and pertussis vaccine (DTaP) can help prevent these diseases. Most children who are vaccinated with DTaP will be protected throughout childhood. Many more children would get these diseases if we stopped vaccinating.

Risks from DTap vaccine

Getting diphtheria, tetanus, or pertussis disease is much riskier than getting DTaP vaccine.
However, a vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of DTaP vaccine causing serious harm, or death, is extremely small.

Mild Problems:

  • Fever (up to about 1 child in 4)
  • Redness or swelling where the shot was given (up to about 1 child in 4)
  • Soreness or tenderness where the shot was given (up to about 1 child in 4)
These problems occur more often after the 4th and 5th doses of the DTaP series than after earlier doses. Sometimes the 4th or 5th dose of DTaP vaccine is followed by swelling of the entire arm or leg in which the shot was given, lasting 1-7 days (up to about 1 child in 30).

Other Mild Problems

  • Fussiness (up to about 1 child in 3)
  • Tiredness or poor appetite (up to about 1 child in 10)
  • Vomiting (up to about 1 child in 50)
These problems generally occur 1-3 days after the shot.
Moderate Problems
  • Seizure (jerking or staring) (about 1 child out of 14,000)
  • Non-stop crying, for 3 hours or more (up to about 1 child out of 1,000)
  • High fever, over 105°F (about 1 child out of 16,000)

Severe Problems

  • Serious allergic reaction (less than 1 out of a million doses)
  • Several other severe problems have been reported after DTaP vaccine. These include:
    • Long-term seizures, coma, or lowered consciousness
    • Permanent brain damage.
    These are so rare it is hard to tell if they are caused by the vaccine.
Controlling fever is especially important for children who have had seizures, for any reason. It is also important if another family member has had seizures. You can reduce fever and pain by giving your child an aspirin-free pain reliever when the shot is given, and for the next 24 hours, following the package instructions.

Saturday, 20 September 2014

TYPES OF VACCINATION [HEPATITIS A]

HEPATITIS A VACCINATION

What is hepatitis A?

Hepatitis A virus (HAV) is present worldwide and is the agent of one of the most widespread infections transmitted via the fecal-oral route. In countries with poor hygiene and consequent wide presence of feces in the environment, the vast majority of subjects is infected within 5 years of age (usually without any sign or symptom of acute hepatitis), thus acquiring life-long immunity. Outbreaks and epidemics are rare due to the high herd immunity level in the population.HAV infection is transmitted both by direct contact with infected subjects and by ingestion of contaminated food and drinks (WHO 1995). Since HAV circulation is diminished but not eliminated, both large epidemics (like the one registered in 1996–97 in Puglia, Italy) (Malfait et al 1996;Lopalco et al 2005) or more limited outbreaks (frequently starting in schools or day-care centers) can occur.

HAV Vaccine

All of the hepatitis A vaccines are highly immunogenic and efficacious. Approximately 97 to 100% of children, adolescents, and adults develop protective antibody levels within 1 month of the first dose of vaccine. Essentially 100% of vaccines develop high antibody titres after completing the 2-dose series, with long-term persistence of protective antibody levels 10 years out from vaccination. In randomized double-blind placebo-controlled trials, 94-100% children were protected against clinical hepatitis A after receiving the equivalent of a single dose.

Here is a picture that shows the Groups recommended for Hepatitis A Vaccine 


Friday, 19 September 2014

TYPES OF VACCINATION [HEPATITIS B]

HEPATITIS B VACCINATION

WHAT IS HEPATITIS B??

Hepatitis B virus (HBV) is transmitted from one person to another through blood and body fluids, and primarily infects the liver. In the United States, it is most commonly spread through sexual contact or injection drug use. Health care workers and others exposed to infected blood or body fluids are also at high risk for infection. Worldwide, it is most commonly spread to infants by their infected mothers.


Hepatitis B can cause:
Acute (short-term) illness. This can lead to:

loss of appetite • diarrhea and vomiting
tiredness • jaundice (yellow skin or eyes)
pain in muscles, joints, and stomach
Acute illness, with symptoms, is more common among adults. Children who become infected usually do not have symptoms.Chronic (long-term) infection. Some people go on to 
develop chronic hepatitis B infection.

Hepatitis B virus is easily spread through contact with the 
blood or other body fluids of an infected person. People can also be infected from contact with a contaminated object, where the virus can live for up to 7 days.
A baby whose mother is infected can be infected at birth;
Children, adolescents, and adults can become infected 
by:
- contact with blood and body fluids through breaks in
the skin such as bites, cuts, or sores;
- contact with objects that have blood or body fluids on
them such as toothbrushes, razors, or monitoring and 
treatment devices for diabetes;
- having unprotected sex with an infected person;
- sharing needles when injecting drugs;
- being stuck with a used needle.

HEPATITIS B VACCINE: Why get vaccinated?

Hepatitis B vaccine can prevent hepatitis B, and the serious consequences of hepatitis B infection, including liver cancer and cirrhosis.Hepatitis B vaccine may be given by itself or in the same shot with other vaccines.Routine hepatitis B vaccination was recommended for 
some U.S. adults and children beginning in 1982, and for all children in 1991. Since 1990, new hepatitis B infections among children and adolescents have dropped by more than 
95%—and by 75% in other age groups.Vaccination gives long-term protection from hepatitis B infection, possibly lifelong.

Who should get HEPATITIS B vaccine and when?


Children and adolescents
• Babies normally get 3 doses of hepatitis B vaccine:
1st Dose: Birth
2nd Dose: 1-2 months of age
3rd Dose: 6-18 months of age
 Some babies might get 4 doses, for example, if a combination vaccine containing hepatitis B is used. (This is a single shot containing several vaccines.) The extra
dose is not harmful.
• Anyone through 18 years of age who didn’t get the vaccine when they were younger should also be vaccinated.
Adults
• All unvaccinated adults at risk for hepatitis B infection should be vaccinated. This includes:
- sex partners of people infected with hepatitis B,
- men who have sex with men,
- people who inject street drugs,
- people with more than one sex partner,
- people with chronic liver or kidney disease,
- people under 60 years of age with diabetes, 
- people with jobs that expose them

Wednesday, 17 September 2014

TYPES OF VACCINATION [POLIO]

POLIO VACCINATION

The Polio Vaccination is the most popular kind of Routine Immunization. This vaccination is given to children during the early stages of their life, that is from 0 to 5 years.
So before we get into details about this vaccination lets try and understand why is this vaccination important.
UNDERSTANDING THE DISEASE {POLIO}
Polio is caused by intestinal viruses that spread from person to person in stool and saliva. Most people infected with polio (approximately 95%) show no symptoms. Minor symptoms can include sore throat, low-grade fever, nausea, and vomiting. Some infected persons (1 to 2%) will have stiffness in the neck, back, or legs without paralysis. Less than 1% of polio infections (about 1 of every 1,000 cases) cause paralysis. In some cases, the poliovirus will paralyze the muscles used to breathe, leaving the victim unable to breathe on his or her own. Many paralyzed persons recover completely. Those who do recover from paralytic polio may be affected 30 to 40 years later, with muscle pain and progressive weakness.
Before the polio vaccine, 13,000 to 20,000 people were paralyzed by polio, and about 1,000 people died from it each year in the United States. Most of those infected were elementary school children so it was often called ‘infantile paralysis.

HISTORY OF POLIO VACCINE
Two types of polio vaccine (OPV, oral polio vaccine, and IPV, inactivated polio vaccine) were created in the 1950s. Both were highly effective in preventing polio. Initially OPV was preferred because it helped to increase community immunity to polio.
However, about 1 out of 2.4 million doses of OPV distributed in the United States actually caused vaccine-associated paralytic polio (VAPP). In an effort to reduce this terrible side effect, a new polio vaccine schedule was recommended in 1997 (two doses of IPV followed by two doses of OPV). The new schedule decreased, but did not guarantee elimination, of vaccine-induced paralytic polio; so, effective in the year 2000, an all-IPV schedule was recommended, and OPV is no longer administered in the U.S. OPV continues to be used in countries where wild polio infections still occur.

TWO TYPES OF POLIO VACCINATION
  • Polio Vaccine Inactivated (IPV)
  • IPV in combination with DTaP (Diphtheria-Tetanus-acellular Pertussis) and hepatitis B vaccines
CURRENT SCENARIO
Normally, immunization is an integrated part of a broader package of mother and child health services. High infant immunization coverage through routine immunization delivers four doses of polio vaccine in the first year of life. However, immunization campaigns for polio carried out in a vertical approach using the health care system have been disruptive for the delivery of other basic services.
At a time when the world is approaching (we hope) the goal of eradication, polio campaigns have become so frequent that there is hardly any space left for basic routine health programs in the last endemic countries. In an environment of constrained resources, health workers are taken away from their routine daily activities—including immunization—to work on the campaigns.
A strong routine country immunization system is essential to achieve and sustain polio-free status. Three trends provide evidence for this:  1) In all three of the last remaining countries with endemic polio (Afghanistan, Pakistan and Nigeria), full, age-appropriate coverage of routine immunization services is low. 2) The last few years have seen outbreaks of polio in 12 countries that already had been declared polio-free, due to virus reintroduction from endemic countries. Those countries which had a strong routine immunization program with high coverage were able to quickly bring polio transmission under control. 3)  Most countries with high coverage of routine immunization never needed campaigns to eliminate polio from their territories.
The World Bank has been supporting polio eradication through targeted efforts in a number of countries including Nigeria, Pakistan and Afghanistan, as well as through broader health programs in countries like Yemen and India. The disease disproportionately affects poor regions and countries with limited fiscal space for disease control programs.  Investments in polio are demonstrably pro-poor, but eradication will benefit all future generations in all countries, rich and poor. There’s no question it would be a global public good.
The costs of stopping polio are substantial—more than should reasonably be borne alone by those countries where the epidemic persists. This requires a more holistic approach, ensuring that systems are in place that can ensure delivery of basic health services, including immunizations. Strengthening health systems and supporting routine immunization, the neglected pillar of GPEI, should both be a high priority.